University Medical Center Management Corporation

University Medical Center Management Corporation was paid $86.90M by Medicaid between Jan 2018 and Dec 2024, across 404 billing codes. Its largest line is 99285, emergency room visit (most serious) — 31% of everything it billed.

33Billing provider infoUNIVERSITY MEDICAL CENTER MANAGEMENT CORPORATION
NEW ORLEANS, LA 70112

33aNPI1568403111assigned 06/08/2006

33bProvider typeGeneral Acute Care Hospital

28Total paid$86.90M

24GClaims2,190,640

24DCodes billed404

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other General Acute Care Hospital providers in Louisiana

Rank by total paid#4 of 96

Median peer was paid$5.17M

This provider vs. median17×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	284,052	$11.60M
2019	275,345	$10.79M
2020	280,228	$11.23M
2021	419,211	$14.31M
2022	370,581	$15.21M
2023	343,547	$13.56M
2024incomplete	217,676	$10.20M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	31%	76,148	66,817	$27.23M
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	12%	47,733	42,762	$10.60M
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	12%	329,842	287,215	$10.15M
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	5.5%	27,414	24,571	$4.76M
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	2.9%	61,212	50,575	$2.55M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	2.4%	31,527	20,443	$2.08M
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	2.3%	10,332	6,062	$1.97M
G0378	Hospital observation service, per hour	1.9%	5,934	2,292	$1.62M
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	1.7%	32,468	27,740	$1.49M
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	1.5%	4,454	3,574	$1.30M
80053	Comprehensive metabolic panel	1.4%	161,996	130,900	$1.18M
96375	Therapeutic injection; each additional sequential IV push	1.1%	17,394	11,933	$959K

392 more codes

G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	14,668	$810K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	25,415	$757K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	138,199	$720K
70450	Computed tomography, head or brain; without contrast material	<1%	3,851	$645K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	16,088	$639K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	14,570	$635K
36415	Collection of venous blood by venipuncture	<1%	305,101	$622K
71046	Radiologic examination, chest; 2 views	<1%	13,978	$595K
74177	Computed tomography, abdomen and pelvis; with contrast material	<1%	1,534	$588K
96361	Intravenous infusion, hydration; each additional hour	<1%	11,216	$475K
95810	Polysomnography; sleep staging with 4 or more additional parameters	<1%	525	$420K
71045	Radiologic examination, chest; single view	<1%	10,824	$408K
87536		<1%	7,554	$406K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	3,487	$363K
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	<1%	14,851	$335K
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	1,683	$305K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	10,342	$296K
83036	Hemoglobin; glycosylated (A1C)	<1%	37,979	$279K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	15,319	$276K
83880		<1%	10,905	$267K
31575		<1%	842	$257K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	6,403	$251K
95886		<1%	2,447	$242K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	7,754	$241K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	7,781	$240K
80061	Lipid panel	<1%	22,507	$239K
80050	General health panel	<1%	6,442	$237K
92014	Ophthalmological services: medical examination and evaluation, comprehensive, established patient	<1%	5,440	$230K
84484		<1%	28,656	$225K
95911		<1%	556	$222K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	10,046	$218K
86360		<1%	6,825	$206K
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	2,782	$201K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	2,346	$196K
92012	Ophthalmological services: medical examination and evaluation, intermediate, established patient	<1%	3,930	$177K
0002A		<1%	5,366	$171K
73564		<1%	1,756	$167K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	742	$165K
86359		<1%	6,935	$162K
0001A		<1%	5,423	$155K
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	<1%	458	$154K
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	951	$144K
J0585	Injection, onabotulinumtoxina, 1 unit	<1%	431	$143K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	<1%	44	$125K
83970		<1%	3,685	$125K
84443	Thyroid stimulating hormone (TSH)	<1%	9,381	$124K
92134		<1%	3,298	$115K
95910		<1%	574	$102K
80305		<1%	9,447	$101K
G0121	Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk	<1%	400	$101K
97803		<1%	9,655	$98K
81025		<1%	17,310	$97K
73610		<1%	1,741	$96K
90674		<1%	6,596	$96K
87522	Neg quan hep c or qual rna	<1%	2,523	$95K
95909		<1%	453	$95K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	843	$93K
96417		<1%	1,305	$92K
86780		<1%	8,101	$92K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	4,567	$91K
90791	Psychiatric diagnostic evaluation	<1%	1,780	$91K
J9271	Injection, pembrolizumab, 1 mg	<1%	15	$91K
84425		<1%	4,907	$87K
85027		<1%	15,937	$80K
83735		<1%	18,855	$79K
92133		<1%	2,052	$78K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	872	$73K
82607		<1%	5,823	$73K
85610		<1%	27,313	$72K
83921		<1%	4,121	$71K
45378	Colonoscopy, flexible; diagnostic, including collection of specimen(s)	<1%	281	$70K
90834	Psychotherapy session, about 45 minutes	<1%	509	$69K
0011A		<1%	2,090	$68K
90935	Hemodialysis procedure with single evaluation by a physician	<1%	298	$66K
0012A		<1%	2,151	$66K
73502		<1%	1,013	$66K
82550		<1%	13,942	$64K
84207		<1%	4,505	$63K
95913		<1%	146	$61K
92083		<1%	2,729	$59K
77386		<1%	158	$59K
80048	Basic metabolic panel (calcium, ionized)	<1%	8,433	$59K
82746		<1%	4,769	$58K
73523		<1%	325	$56K
73130		<1%	1,062	$56K
85730		<1%	14,524	$52K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	<1%	38	$52K
86803		<1%	4,641	$52K
84439		<1%	7,137	$51K
72125	Computed tomography, cervical spine; without contrast material	<1%	301	$50K
83090		<1%	5,680	$50K
84252		<1%	4,550	$50K
81001		<1%	22,688	$49K
82525		<1%	4,751	$49K
86141		<1%	4,333	$47K
83605		<1%	5,933	$46K
95811		<1%	52	$45K
84630		<1%	4,756	$45K
J2469	Injection, palonosetron hcl, 25 mcg	<1%	2,070	$44K
0004A		<1%	1,189	$44K
86481		<1%	742	$43K
77336		<1%	440	$42K
82390		<1%	4,571	$40K
95912		<1%	120	$40K
96523		<1%	1,365	$39K
73562		<1%	803	$37K
84466		<1%	3,766	$37K
11721		<1%	1,007	$37K
70498		<1%	110	$36K
31231		<1%	101	$36K
82728		<1%	3,410	$36K
J1453	Injection, fosaprepitant, 1 mg	<1%	356	$34K
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	81	$33K
87340		<1%	3,904	$32K
91200		<1%	247	$32K
31525		<1%	151	$32K
84600		<1%	2,985	$31K
84100		<1%	10,872	$31K
96415		<1%	606	$31K
92250		<1%	387	$31K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	294	$30K
93356		<1%	307	$30K
87086	Culture, bacterial; quantitative colony count, urine	<1%	4,726	$30K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	500	$29K
72100		<1%	625	$29K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	1,514	$29K
96900		<1%	976	$28K
84481		<1%	2,835	$27K
83690		<1%	5,612	$27K
20610		<1%	125	$27K
96367		<1%	557	$26K
G0433	Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening	<1%	3,147	$26K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	3,372	$25K
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	7,756	$25K
0031A		<1%	896	$25K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	324	$24K
73110		<1%	484	$23K
11056		<1%	658	$23K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	824	$23K
73630		<1%	456	$22K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	1,080	$22K
97802		<1%	1,333	$22K
52000		<1%	88	$22K
99215	Doctor's office visit, returning patient (complex)	<1%	530	$21K
76536		<1%	183	$20K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	883	$20K
86003		<1%	261	$20K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	78	$20K
29581		<1%	337	$19K
83540		<1%	3,802	$18K
97161		<1%	376	$18K
73140		<1%	376	$18K
84134		<1%	3,285	$18K
95816		<1%	84	$18K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	10,632	$17K
Q5103	Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg	<1%	16	$16K
86706		<1%	1,698	$16K
84153		<1%	1,085	$15K
90750		<1%	221	$15K
82962		<1%	6,914	$15K
99282	Emergency department visit for the evaluation and management, low to moderate severity	<1%	135	$14K
80375		<1%	1,622	$14K
86704		<1%	1,364	$14K
97763		<1%	294	$14K
82570		<1%	3,316	$13K
80323		<1%	1,502	$13K
95908		<1%	89	$13K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	3,413	$13K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	3,586	$12K
82947		<1%	4,886	$12K
80329		<1%	1,118	$12K
J1050	Injection, medroxyprogesterone acetate, 1 mg	<1%	595	$12K
97597		<1%	208	$12K
29580		<1%	275	$12K
86708		<1%	1,111	$12K
20611		<1%	52	$11K
81003		<1%	7,796	$11K
80074		<1%	378	$11K
81002		<1%	3,592	$11K
90837	Psychotherapy session, about an hour	<1%	59	$10K
J7050	Infusion, normal saline solution, 250 cc	<1%	632	$10K
70496		<1%	32	$10K
G0475	Hiv antigen/antibody, combination assay, screening	<1%	968	$10K
86140		<1%	2,225	$10K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	3,502	$9K
70486		<1%	74	$9K
82043		<1%	2,120	$9K
J7030	Infusion, normal saline solution , 1000 cc	<1%	890	$9K
92229		<1%	378	$9K
86480		<1%	174	$8K
81420	Fetal chromosomal aneuploidy genomic sequence analysis panel	<1%	18	$8K
64721		<1%	27	$8K
90833	Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on)	<1%	71	$8K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	13,385	$8K
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	16	$8K
72110		<1%	96	$8K
90715		<1%	294	$7K
11720		<1%	159	$7K
84480		<1%	1,113	$7K
77063	Screening digital breast tomosynthesis, bilateral	<1%	105	$7K
86850		<1%	1,589	$7K
72040		<1%	160	$6K
85651		<1%	1,851	$6K
84681		<1%	4,484	$6K
0003A		<1%	185	$6K
96411		<1%	76	$6K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	400	$6K
93000		<1%	70	$6K
82105		<1%	485	$6K
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	<1%	1,720	$6K
77065	Tomosynthesis, mammo	<1%	82	$6K
96416		<1%	17	$5K
64615		<1%	27	$5K
J7120	Ringers lactate infusion, up to 1000 cc	<1%	365	$5K
94726		<1%	30	$5K
72141		<1%	12	$5K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	171	$5K
90832	Psychotherapy session, about 30 minutes	<1%	93	$5K
86408		<1%	165	$5K
93923		<1%	77	$5K
0054A		<1%	124	$4K
90670		<1%	23	$4K
86762		<1%	278	$4K
87210		<1%	921	$4K
96376		<1%	89	$4K
84702		<1%	420	$4K
93350		<1%	13	$4K
0124A		<1%	223	$4K
86900		<1%	1,689	$4K
90746		<1%	73	$4K
86901		<1%	1,712	$4K
77300		<1%	15	$4K
86357		<1%	219	$4K
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	740	$4K
93017		<1%	17	$4K
86160		<1%	257	$4K
97760		<1%	73	$3K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	173	$3K
90677		<1%	44	$3K
76642		<1%	45	$3K
J1170	Injection, hydromorphone, up to 4 mg	<1%	1,347	$3K
90651		<1%	15	$3K
95885		<1%	30	$3K
J9190	Injection, fluorouracil, 500 mg	<1%	171	$3K
86235		<1%	61	$3K
G0105	Colorectal cancer screening; colonoscopy on individual at high risk	<1%	18	$3K
19281		<1%	91	$3K
77073		<1%	25	$3K
83993		<1%	171	$3K
10005		<1%	29	$2K
80320		<1%	816	$2K
80349		<1%	214	$2K
82378		<1%	155	$2K
88112		<1%	107	$2K
80069		<1%	382	$2K
73030		<1%	30	$2K
86355		<1%	131	$2K
72050		<1%	28	$2K
20605		<1%	12	$2K
J2270	Injection, morphine sulfate, up to 10 mg	<1%	617	$2K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	2,586	$2K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	2,945	$2K
81596		<1%	49	$2K
72082		<1%	14	$2K
94729		<1%	30	$2K
87088		<1%	228	$2K
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation	<1%	17	$2K
80179		<1%	572	$2K
80143		<1%	570	$1K
G0109	Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes	<1%	46	$1K
J1790	Injection, droperidol, up to 5 mg	<1%	495	$1K
C1713	Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	<1%	29	$1K
0399T		<1%	14	$1K
29125		<1%	16	$1K
90734		<1%	14	$1K
73590		<1%	29	$1K
93880		<1%	13	$1K
86225		<1%	126	$1K
90739		<1%	30	$1K
72120		<1%	12	$1K
J2704	Injection, propofol, 10 mg	<1%	14,953	$1K
85007		<1%	596	$1K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	34	$1K
86593		<1%	327	$1K
76830	Ultrasound, transvaginal	<1%	12	$1K
87077		<1%	136	$1K
92004	Ophthalmological services: medical examination and evaluation, comprehensive, new patient	<1%	36	$1K
84156		<1%	420	$1K
86703		<1%	103	$953.85
J1644	Injection, heparin sodium, per 1000 units	<1%	247	$920.75
J7040	Infusion, normal saline solution, sterile (500 ml = 1 unit)	<1%	48	$914.90
85384		<1%	186	$910.45
91320		<1%	28	$884.90
82785		<1%	69	$869.92
90632		<1%	14	$845.51
82150		<1%	158	$824.16
87102		<1%	134	$790.54
87480		<1%	42	$748.50
90472	Immunization administration, each additional vaccine (list separately)	<1%	315	$741.04
82180		<1%	92	$729.75
69210		<1%	20	$696.08
J0640	Injection, leucovorin calcium, per 50 mg	<1%	27	$683.34
92227		<1%	66	$680.07
90661		<1%	43	$649.68
J1030	Injection, methylprednisolone acetate, 40 mg	<1%	90	$602.12
94618		<1%	13	$576.59
88342		<1%	1,934	$575.06
80353		<1%	52	$570.12
87660		<1%	39	$561.40
87510		<1%	39	$561.40
85660		<1%	109	$560.72
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	261	$557.93
C1894	Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	<1%	25	$540.63
92285		<1%	12	$510.48
87206		<1%	135	$506.66
97165		<1%	14	$506.45
99152		<1%	869	$491.73
86787		<1%	49	$486.62
0051A		<1%	17	$466.36
J2919	Injection, methylprednisolone sodium succinate, 5 mg	<1%	208	$463.84
87186		<1%	46	$433.97
87516		<1%	13	$428.89
87081		<1%	28	$421.97
95249		<1%	15	$420.49
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	133	$416.98
90686		<1%	16	$388.50
99153	Mod sedat endo service >5yrs	<1%	302	$366.20
C1769	Guide wire	<1%	14	$355.23
83010		<1%	28	$336.96
84590		<1%	31	$325.08
J2003	Injection, lidocaine hydrochloride, 1 mg	<1%	162	$302.22
86038		<1%	29	$295.11
A9585	Injection, gadobutrol, 0.1 ml	<1%	15	$283.63
G0463	Hospital outpatient clinic visit for assessment and management of a patient	<1%	11,412	$273.60
97804		<1%	149	$266.94
J0690	Injection, cefazolin sodium, 500 mg	<1%	555	$244.08
J3475	Injection, magnesium sulfate, per 500 mg	<1%	32	$232.47
84403		<1%	14	$232.29
C1751	Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis)	<1%	2,820	$230.43
82565		<1%	42	$205.66
87040		<1%	12	$196.08
90656		<1%	197	$195.48
82977		<1%	28	$194.16
88173		<1%	23	$179.45
86705		<1%	15	$164.78
91300		<1%	13,069	$146.55
83615		<1%	30	$144.96
J2060	Injection, lorazepam, 2 mg	<1%	49	$141.99
83883		<1%	28	$118.32
90480		<1%	57	$118.32
J1040	Injection, methylprednisolone acetate, 80 mg	<1%	14	$103.30
J1650	Injection, enoxaparin sodium, 10 mg	<1%	25	$91.80
90662		<1%	16	$86.52
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	1,246	$75.21
Q0163	Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen	<1%	159	$56.93
99443		<1%	40	$54.07
J0330	Injection, succinylcholine chloride, up to 20 mg	<1%	183	$48.93
J1010	Injection, methylprednisolone acetate, 1 mg	<1%	17	$47.77
84550		<1%	16	$45.45
A6258	Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing	<1%	159	$41.07
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	16	$40.49
J1171	Injection, hydromorphone, 0.1 mg	<1%	17	$36.80
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	<1%	21	$34.50
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	31	$30.62
A6223	Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing	<1%	1,211	$21.67
Q3014	Telehealth originating site facility fee	<1%	2,438	$16.37
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	25,490	$13.78
E0191	Heel or elbow protector, each	<1%	123	$12.42
J2370	Injection, phenylephrine hcl, up to 1 ml	<1%	91	$11.43
J1596	Injection, glycopyrrolate, 0.1 mg	<1%	118	$8.76
J2795	Injection, ropivacaine hydrochloride, 1 mg	<1%	14	$4.79
Q0244	Injection, casirivimab and imdevimab, 1200 mg	<1%	71	$0.60
A6222	Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing	<1%	47	$0.28
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	<1%	208	$0.04
91312		<1%	308	$0.02
99001		0%	14,100	$0.00
82172		0%	32	$0.00
88355		0%	109	$0.00
90611		0%	271	$0.00
99442		0%	41	$0.00
80348		0%	121	$0.00
D1110	Prophylaxis - adult	0%	20	$0.00
91301		0%	4,735	$0.00
91303		0%	942	$0.00
J0131	Injection, acetaminophen, not otherwise specified,10 mg	0%	29	$0.00
D0140	Limited oral evaluation - problem focused	0%	48	$0.00
G0008	Administration of influenza virus vaccine	0%	65	$0.00
93289		0%	15	$0.00
J2371	Injection, phenylephrine hydrochloride, 20 micrograms	0%	16	$0.00
91305		0%	184	$0.00
C9290	Injection, bupivacaine liposome, 1 mg	0%	14	$0.00
99441		0%	33	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMASTERTON, WILLIAM (CEO)